Hormonal
A higher triglyceride-glucose (TyG) index, serving as a surrogate marker for insulin resistance, is significantly associated with increased risks of composite cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, and incident type 2 diabetes.
Your risk for heart disease and diabetes is closely linked to your insulin resistance, which can be estimated using a simple calculation from your fasting triglyceride and glucose levels. This risk is not uniform; it is significantly higher for people living in low- and middle-income countries. Regular monitoring of these markers can help identify those at high risk for cardiovascular events and diabetes, allowing for earlier intervention.
After adjusting for all other variables, the risk of developing cardiovascular diseases increased across tertiles of the baseline TyG index. Compared with the lowest tertile of the TyG index, the highest tertile (tertile 3) was associated with a greater incidence of the composite outcome (HR 1·21; 95% CI 1·13–1·30), myocardial infarction (1·24; 1·12–1·38), stroke (1·16; 1·05–1·28), and incident type 2 diabetes (1·99; 1·82–2·16).
Why this rating
Large-scale prospective cohort study (n=141,243) across 22 countries with long follow-up (median 13.2 years) and multivariable adjustment, though observational design limits causal inference.
Source
Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study
Patricio López‐Jaramillo et al. · The Lancet Healthy Longevity · 2022
DOI 10.1016/s2666-7568(22)00247-1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →